MedTrace Logo

A Phase II Clinical Trial of the Safety and Efficacy of SAL0120 in Patients With Chronic Kidney Disease (CKD)

NCT07716618 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 320

Last updated 2026-07-21

No results posted yet for this study

Summary

This study is a multicenter, randomized, double-blind, placebo-controlled, parallel-design clinical trial designed to investigate the efficacy and safety of different doses of sal0120 tablets in patients with CKD.

Conditions

Interventions

DRUG

SAL0120 1mg

SAL0120 1mg

DRUG

SAL0120 2mg

SAL0120 2mg

DRUG

SAL0120 4mg

SAL0120 4mg

DRUG

Placebo

placebo

Sponsors & Collaborators

  • Salubris (Suzhou) Pharmaceutical Co., Ltd.

    collaborator UNKNOWN

  • Shenzhen Salubris Pharmaceuticals Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-01-17
Primary Completion
2026-05-27
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07716618 on ClinicalTrials.gov